NEWARK, DE--(Marketwire - June 01, 2009) - Isogen LLC announced today that it has closed on a credit facility with Wilmington Trust totaling $7 million. The facility is made up of three term loans which will be used for purchasing machinery and equipment, working capital, and recasting existing debt.
"I'm pleased that our credit facility with Wilmington Trust has closed. This financing will enable us to expedite our growth strategy. Through the expansion of our Science Center we will double our capacity, and increase our revenue at an accelerated rate," shared Les Edwards, Isogen's CEO.
About Isogen
Through its Science Center in Newark, Delaware, Isogen provides advanced sterile manufacturing for potent and non-potent therapeutics for the critical clinical/commercial scale manufacturing transition. The Company delivers a fully integrated suite of services including formulation, tech transfer, laboratory, and validation services for the contract filling of liquids and lyophilized formulations for vaccines, mAbs, and other synthetic and biologically derived therapeutics. For further information, contact Robin Uhl, ruhl@isogenllc.com, 201-394-1927.
Information contained in this press release, other than historical
information, may be considered forward-looking in nature as such it is
based upon certain assumptions and is subject to various risks and
uncertainties, which may not be controllable by the Company. To the extent
that these assumptions prove to be incorrect, or should any of these risks
or uncertainties materialize, the actual results may vary materially from
those that were anticipated.
